CRISPR Therapeutics (CRSP) Stock Looks Fully Valued As It Names A New CTO
Yahoo Finance · Nov 3, 2026 · Crispr Therapeutics AG (CRSP)
CRISPR Therapeutics has been a volatile ride for shareholders, and the latest moves raise a straightforward question for anyone looking at the stock today. Is the current share price meaningfully supported by what sits on its balance sheet in terms of book value, or is the market asking you to pay well above the company’s accounting foundation? Over the past 5 years, the share price has fallen 46.9%, which puts the focus squarely on whether the current valuation can still be anchored to book...
Not investment advice. Headline and summary only, not a full reprint.